Breaking News - Candlesense

The Trade Desk Reports Second Quarter 2025 Financial Results

LOS ANGELES--(BUSINESS WIRE)--The Trade Desk, Inc. (“The Trade Desk,” the “Company” or “we”) (NASDAQ: TTD), a provider of a global technology platform for buyers of advertising, today announced fin...

How might the results affect valuation multiples (e.g., P/E, EV/EBITDA) relative to industry peers? Did the company provide updates on AI/ML capabilities or upcoming product enhancements that may influence future growth? What macro‑economic factors (e.g., ad‑spend slowdown, inflation) could affect the company's outlook moving forward?

Symbol: TTD

Earnings

20 days ago

Read more businesswire

Owlet to Simplify Capital Structure Through Exchange of Series A and Series B Warrants for Common Stock

LEHI, Utah--(BUSINESS WIRE)---- $owlt #investorrelations--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced an agreement with a majority o...

Are there any comparable recent transactions by peers that can provide insight into potential market response? Will the exchange have any effect on the company’s dividend policy or share‑repurchase program? How might this capital‑structure simplification influence analyst coverage and earnings forecasts?

Symbol: OWLT

Capital

20 days ago

Read more businesswire

Expedia Group Reports Second Quarter 2025 Results

SEATTLE--(BUSINESS WIRE)--Expedia Group, Inc. (NASDAQ: EXPE) announced financial results today for the second quarter ended June 30, 2025. Second Quarter Highlights Booked room nights grew 7%, prim...

What macroeconomic or travel- demand trends could influence Expedia's performance in the upcoming quarters? How will the recent results affect the stock's valuation multiples relative to peers? What is the company's cash flow situation and guidance for capital expenditures and stock buybacks?

Symbol: EXPE

Earnings

20 days ago

Read more businesswire

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying it...

Are there any macro or sector‑specific factors (e.g., biotech funding environment, FDA policy shifts) that could influence Janux's valuation post‑release? What is the market's reaction to the earnings release, and are there any notable changes in institutional ownership or short‑interest? Did the company disclose any changes in its clinical trial timelines or enrollment rates that could affect future milestones?

Symbol: JANX

Earnings

20 days ago

Read more businesswire

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is h...

Did the company address any changes in its commercial strategy or potential product launch timelines that could affect future revenue streams? What are the potential upside or downside risks associated with the upcoming regulatory milestones for the Phase 3 candidates? How does Arrowhead's Q3 performance and pipeline maturity compare to its direct competitors in the RNA‑targeted therapeutics space?

Symbol: ARWR

Earnings

20 days ago

Read more businesswire

VTEX Reports Second Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--VTEX (NYSE: VTEX), the backbone for connected commerce, today announced results for the second quarter of 2025 ended June 30, 2025. VTEX results have been prepared in acc...

Are there any macroeconomic or regulatory factors highlighted in the release that could influence VTEX's future performance? Did VTEX announce any strategic initiatives, partnerships, or product launches that could impact its competitive positioning? What is the market's reaction to the earnings release so far, and how is the stock price trending post‑announcement?

Symbol: VTEX

Earnings

20 days ago

Read more businesswire

Consensus Cloud Solutions, Inc. Reports Second Quarter 2025 Results; Reaffirms Full Year 2025 Revenue and Adjusted EBITDA Guidance; Raises Full Year 2025 Adjusted Earnings Per Diluted Share Guidance

LOS ANGELES--(BUSINESS WIRE)--Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) today reported financial results for the second quarter of 2025. “We continued our momentum through Q2 returning to tota...

What is the level of customer concentration and churn rates—do the results indicate any changes in customer retention or churn risk? What is the trend in cash flow, debt levels, and liquidity ratios after Q2—are there any concerns about the balance sheet? How does the updated guidance impact the implied upside/downside risk for options traders (e.g., implied volatility and strike selection)?

Symbol: CCSI

Earnings

20 days ago

Read more businesswire

Finward Bancorp Announces Termination of Consent Order

MUNSTER, Ind.--(BUSINESS WIRE)--Finward Bancorp (Nasdaq: FNWD) (the “Bancorp”), the holding company for Peoples Bank (the “Bank”), today announced that on August 6, 2025 the Federal Deposit Insuran...

Is there any anticipated impact on the bank’s dividend policy or share repurchase plans following the regulatory relief? Will the termination lead to any changes in the bank’s capital adequacy ratios or affect its upcoming earnings guidance? How might this development influence institutional investors’ perception of Finward Bancorp’s governance and risk management practices?

Symbol: FNWD

Regulation

20 days ago

Read more businesswire

Nerdy Announces Second Quarter 2025 Financial Results

ST. LOUIS--(BUSINESS WIRE)--Nerdy Inc. (NYSE: NRDY) today announced financial results for the second quarter ended June 30, 2025. “Q2 proved that our Live+AI™ strategy is a growth engine,” said Chu...

Are there any upcoming product launches or partnerships that could further influence revenue growth? How might the market react to the AI tool rollout, and what is the expected impact on the stock price? What potential risks or headwinds were mentioned that could impact future quarters?

Symbol: NRDY

Earnings

20 days ago

Read more businesswire

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoim...

What are the implications of the site activation numbers for future commercial rollout? How does the reported sentiment (60) align with market sentiment and analyst ratings? What are the potential catalysts (e.g., data readout, FDA interactions) that could move the stock price?

Symbol: ACET

Earnings

20 days ago

Read more businesswire